Norethynodrel

Drug #2015

A synthetic progestational hormone with actions and uses similar to those of progesterone. It has been used in the treatment of functional uterine bleeding and endometriosis. As a contraceptive, it has usually been administered in combination with mestranol.

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin.

Molecular Weight: 298.4 · Solubility in Water: Very Slightly soluble · Solubility in Alcohol: Springly Soluble · Non-proprietary name: Norethynodrel.

Pharmacokinetics

Elimination: it is metabolised via Hepatic.

Indications

Norethynodrel is primarily indicated in conditions like Abnormal uterine bleeding, Contraception, Endometriosis, Menstruation disorders.

Contraindications

Norethynodrel is contraindicated in conditions like Thrombosis, Vaginal bleeding, Amenorrhoea.

Dosage

None recorded.

Drug Interactions

None recorded.

Side Effects

Norethynodrel in overdosage may give rise to further complications which include Thromboembolism, Hirsutism.

The signs and symptoms that are produced after acute overdosage of Norethynodrel are Diarrhea, Jaundice , Headache, Insomnia, Pain, Pre-menstrual syndrom.

Norethynodrel is known to cause more or less tolerable side effects which are usually transient. These include Fatigue, GI disturbance, Gynecomastia, Headache, Mental depression, Weight gain.

Warnings / Precautions

Norethynodrel should be used with caution in patients with cardiovascular or renal impairment, diabetes mellitus, asthma, epilepsy, and migraine, or other conditions which may be aggravated by fluid retention. They should also be used with care in persons with a history of depression. High doses should be used with caution in patients susceptible to thromboembolism. Norethynodrel should not be given to patients with undiagnosed vaginal bleeding, nor to those with a history or current high risk of arterial disease and should generally be avoided in hepatic impairment, especially if severe. Unless Norethynodrel are being used as part of the management of breast or genital-tract carcinoma they should not be given to patients with these conditions.

Interference in Pathology

Norethynodrel may interfere in the diagnosis of Abnormal LFTs .

Available Brands

None recorded.

Drug Classification

1.18.3.1 — Hormonal contraceptives